mFOLFOX6
Stories
-
FDA approves atezolizumab with chemotherapy for Stage III dMMR colon cancer
On October 8, 2026, the FDA approved atezolizumab (Tecentriq) in combination with a fluoropyrimidine and oxaliplatin for adult and pediatric patients two years of age and older with Stage III mismatch repair deficient colon cancer. The approval also covers Tecentriq Hybreza for patients 12 years of age and older who weigh 40 kg or greater.